MADISON, Wis.—Promega Corp. and SignalChem Pharmaceuticals are teaming up to jointly introduce a new kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome.
Use of the single platform will enable scientists to easily profile lead compounds in their own laboratories in a cost-effective manner—with no loss in sensitivity, the companies say.
Promega is the sole distributor of kinase enzymes systems from British Columbia, Canada-based SignalChem. Each kinase enzyme system will be available as a stand-alone enzyme system or will be sold together with the company's ADP-Glo Assay.
According to Neal Cosby, Promega's strategic marketing manager for drug screening, SignalChem proved to be an attractive partner for the collaboration because of its expertise in producing and purifying kinase proteins.
"We tested a number of sources and found SignalChem's to be very high-quality," he says, also explaining that the partnership will focus on the kinase customer. "Our focus is to provide a complete yet robust kinase assay system by combining SignalChem's kinase enzyme materials with Promega's sensitive detection technology."
Cosby points out that the complete solution is accomplished by combining an expanding series of kinase enzyme systems with the ADP-Glo Kinase Assay.
The kinase enzyme systems, used in concert with the new universal, bioluminescent ADP-Glo Kinase Assay, provide all of the necessary tools and give drug screeners ease to profile inhibitors against the human kinome for off-target effects.
As Cosby points out, there are advantages to the single platform.
"The single platform, based on our luminescent ATP detection technology, allows researchers to screen and profile kinase inhibitors without having to use radioactivity and as a universal assay, it can address a wide range of kinase types (e.g., lipid, sugars)," he notes.
Each kinase system is composed of a unique protein kinase enzyme, cognate kinase substrate and enzyme buffer. All of the kinase enzyme systems have been optimized and QC'd with the ADP-Glo Assay.
Cosby explains the ADP-Glo Kinase Assay is as sensitive as radiometric kinase assays and is quickly replacing such traditional technology.
"Although the Promega ADP-Glo Kinase Assay is the easiest and most sensitive detection technology, it does not include any kinase content," he says. "Kinase researchers appreciate the ease of obtaining everything they need to profile the inhibitor molecules from a single source."
The addition of SignalChem's kinase reagents will also provide a boost to Promega's ADP-Glo detection assay.
"This partnering of SignalChem's kinase reagents with the Promega ADP-Glo detection assay for kinases is an ideal fit," says Jasbinder Sanghera, president and CSO of SignalChem Pharmaceuticals. "Now, researchers can obtain all the necessary components to test protein kinase inhibition from a single source, while still obtaining the level of sensitivity obtained with traditional radiometric assays."
Moreover, Cosby says the partnership hopes to build upon the success of Promega's ADP-Glo Kinase Assay.
"We expect to see researchers using the kinase enzyme systems in combination with the kinase detection assay to advance their profiling program, not just in industrial setting, but in academia as well," he says. "The flexible approach allows a customer to pick only the specific kinase enzyme systems of interest to them. There are additional opportunities to combine SignalChem content and Promega detection technologies to better serve discovery scientists."
Use of the single platform will enable scientists to easily profile lead compounds in their own laboratories in a cost-effective manner—with no loss in sensitivity, the companies say.
Promega is the sole distributor of kinase enzymes systems from British Columbia, Canada-based SignalChem. Each kinase enzyme system will be available as a stand-alone enzyme system or will be sold together with the company's ADP-Glo Assay.
According to Neal Cosby, Promega's strategic marketing manager for drug screening, SignalChem proved to be an attractive partner for the collaboration because of its expertise in producing and purifying kinase proteins.
"We tested a number of sources and found SignalChem's to be very high-quality," he says, also explaining that the partnership will focus on the kinase customer. "Our focus is to provide a complete yet robust kinase assay system by combining SignalChem's kinase enzyme materials with Promega's sensitive detection technology."
Cosby points out that the complete solution is accomplished by combining an expanding series of kinase enzyme systems with the ADP-Glo Kinase Assay.
The kinase enzyme systems, used in concert with the new universal, bioluminescent ADP-Glo Kinase Assay, provide all of the necessary tools and give drug screeners ease to profile inhibitors against the human kinome for off-target effects.
As Cosby points out, there are advantages to the single platform.
"The single platform, based on our luminescent ATP detection technology, allows researchers to screen and profile kinase inhibitors without having to use radioactivity and as a universal assay, it can address a wide range of kinase types (e.g., lipid, sugars)," he notes.
Each kinase system is composed of a unique protein kinase enzyme, cognate kinase substrate and enzyme buffer. All of the kinase enzyme systems have been optimized and QC'd with the ADP-Glo Assay.
Cosby explains the ADP-Glo Kinase Assay is as sensitive as radiometric kinase assays and is quickly replacing such traditional technology.
"Although the Promega ADP-Glo Kinase Assay is the easiest and most sensitive detection technology, it does not include any kinase content," he says. "Kinase researchers appreciate the ease of obtaining everything they need to profile the inhibitor molecules from a single source."
The addition of SignalChem's kinase reagents will also provide a boost to Promega's ADP-Glo detection assay.
"This partnering of SignalChem's kinase reagents with the Promega ADP-Glo detection assay for kinases is an ideal fit," says Jasbinder Sanghera, president and CSO of SignalChem Pharmaceuticals. "Now, researchers can obtain all the necessary components to test protein kinase inhibition from a single source, while still obtaining the level of sensitivity obtained with traditional radiometric assays."
Moreover, Cosby says the partnership hopes to build upon the success of Promega's ADP-Glo Kinase Assay.
"We expect to see researchers using the kinase enzyme systems in combination with the kinase detection assay to advance their profiling program, not just in industrial setting, but in academia as well," he says. "The flexible approach allows a customer to pick only the specific kinase enzyme systems of interest to them. There are additional opportunities to combine SignalChem content and Promega detection technologies to better serve discovery scientists."
